Asymmetric dimethylarginine (ADMA): Is really a biomarker for cardiovascular prognosis?

被引：10
|
作者：
Tousoulis, Dimitris [1 ]
Siasos, Gerasimos [1 ,2 ]
Oikonomou, Evangelos [1 ]
Stougianos, Pavlos [2 ]
Papageorgiou, Nikolaos [1 ]
机构：
[1] Univ Athens, Sch Med, Hippokrat Hosp, Cardiol Dept 1, GR-11527 Athens, Greece
[2] Univ Athens, Sch Med, Dept Biol Chem, GR-11527 Athens, Greece
来源：
INTERNATIONAL JOURNAL OF CARDIOLOGY | 2011年 / 153卷 / 02期
关键词：
Asymmetric dimethylarginine; Biomarker; Cardiovascular disease; Atherosclerosis; CORONARY-ARTERY-DISEASE; STAGE RENAL-DISEASE; L-ARGININE; PLASMA-LEVELS; RISK; EVENTS; MORTALITY; MARKER; DEATH;
D O I：
10.1016/j.ijcard.2011.08.070
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：123 / 125
页数：3
相关论文
共 50 条
  • [41] ASYMMETRIC DIMETHYLARGININE (ADMA) AND ENDOTHELIAL DYSFUNCTION: IMPLICATIONS FOR ATHEROGENESIS
    Paes Landim, Mauricio Batista
    Casella Filho, Antonio
    Palandri Chagas, Antonio Carlos
    CLINICS, 2009, 64 (05) : 471 - 478
  • [42] Asymmetric dimethylarginine (ADMA) in the aqueous humor of diabetic patients
    Sugai, Motohiko
    Ohta, Akio
    Ogata, Yuji
    Nakanishi, Minoru
    Ueno, Satoki
    Kawata, Takehiro
    Saito, Nobuhiko
    Tanaka, Yasushi
    ENDOCRINE JOURNAL, 2007, 54 (02) : 303 - 309
  • [43] The liver is an important organ for elimination of asymmetric dimethylarginine (ADMA).
    Nijveldt, R
    Teerlink, T
    Siroen, M
    van Lambalgen, A
    Rauwerda, J
    van Leeuwen, P
    HEPATOLOGY, 2002, 36 (04) : 175A - 175A
  • [44] Asymmetric dimethylarginine (ADMA) is associated with incident cardiovascular disease in the general population. The Hoorn study
    Teerlink, T.
    Heine, R. J.
    Nijpels, G.
    Bouter, L. M.
    Stehouwer, C. D. A.
    Dekker, J. M.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 23 - 23
  • [45] Asymmetric dimethylarginine (ADMA) as a cardiovascular risk factor in end-stage renal disease (ESRD)
    Carmine Zoccali
    Francesca Mallamaci
    Giovanni Tripepi
    European Journal of Clinical Pharmacology, 2006, 62 : 131 - 135
  • [46] Asymmetric dimethylarginine (ADMA) as a cardiovascular risk factor in end-stage renal disease (ESRD)
    Zoccali, C
    Mallamaci, F
    Tripepi, G
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (Suppl 1) : 131 - 135
  • [47] The role of asymmetric dimethylarginine (ADMA) and leptin in hypertensive patients
    Atamer, A.
    Ilhan, N.
    Kocylgit, Y.
    Toprak, G.
    Ozbay, M.
    Celik, Y.
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2008, 36 (01) : 54 - 62
  • [48] Raised asymmetric dimethylarginine (ADMA) in ischaemic skeletal muscle
    Tsui, J. C. S.
    Shi-wen, X.
    Mehdizadeh, A.
    Joshi, D.
    Dashwood, M. R.
    Lawrence, D.
    Baker, D. M.
    BRITISH JOURNAL OF SURGERY, 2010, 97 : 39 - 39
  • [49] The role of asymmetric dimethylarginine (ADMA) and leptin in hypertensive patients
    Atamer, A.
    Ilan, N.
    Kocyigit, Y.
    Toprak, G.
    Ozbay, M.
    Celik, Y.
    ATHEROSCLEROSIS SUPPLEMENTS, 2007, 8 (01) : 115 - 115
  • [50] Effect of asymmetric dimethylarginine (ADMA) on heart failure development
    Liu, Xiaoyu
    Hou, Lei
    Xu, Dachun
    Chen, Angela
    Yang, Liuqing
    Zhuang, Yan
    Xu, Yawei
    Fassett, John T.
    Chen, Yingjie
    NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 2016, 54 : 73 - 81
12345